Ahead of the Bell: Cephalon falls on Nuvigil delay
THE ASSOCIATED PRESS March 30, 2010
Cephalon Inc. shares dipped in premarket trading Tuesday after regulators held up marketing approval for its drug Nuvigil as a treatment for jet lag.
After the markets closed on Monday, Cephalon said it received a response to its application. Cephalon said the Food and Drug Administration told Cephalon it had questions about the data from the clinical trials that are being used to support its new application.
Más
Entradas
No hay comentarios:
Publicar un comentario